Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Clofazimine

A Review

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Clofazimine is useful in the treatment of Hansen’s disease (leprosy) and some dermatological disorders, and is currently being used in drug regimens for patients with human immunodeficiency viral infections who are also infected with Mycobacterium avium complex.

After an oral dose, absorption is variable, but when given in an oil-wax suspension is approximately 70%. Administration with food appears to increase the peak plasma drug concentration and reduce the time to peak level. Data on the volume of distribution and percentage or type of protein binding are not available; however, the drug undergoes extensive tissue distribution. Clofazimine does not cross the blood-brain barrier, but does cross the placenta, and is found in human breast milk.

To date 3 urinary metabolites have been identified in man, but their biological activity is unknown. A substantial portion of the unchanged drug is excreted in faeces. The elimination half life is variable, with values as long as 70 days being quoted in the literature.

Frequently reported side effects of clofazimine are hyperpigmentation of the skin and conjunctiva, and abdominal pain. These resolve upon cessation of therapy. Biochemical and haematological adverse effects have been reported, but are generally not clinically relevant. Pharmacokinetic drug interactions of potential clinical significance have been observed with dapsone, oestrogen, rifampicin and vitamin A.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Acocella G. Clinical pharmacokinetics of rifampicin. Clinical Pharmacokinetics 3: 108–127, 1978

    Article  PubMed  CAS  Google Scholar 

  • Armstrong D, Gold JWM, Dryjanski J, Whimbey E, Polsky B, et al. Treatment of infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 103: 738–743, 1985

    PubMed  CAS  Google Scholar 

  • Baciewicz AM, Self TM. Rifampicin drug interactions. Southern Medical Journal 78: 714–718, 1985

    Article  PubMed  CAS  Google Scholar 

  • Baciewicz AM, Self TM, Bekemeyer WB. Update on rifampicin drug interactions. Archives of Internal Medicine 147: 565–568, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bajaj AK, Gupta SC, Sinha SN, Govil DC, Gaur UC. Renal functional status in lepromatous leprosy. International Journal of Leprosy 49: 37–41, 1981

    CAS  Google Scholar 

  • Banerjee DK, Ellard GA, Gammon PT, Waters MFR. Some observations on the pharmacology of clofazimine (B663). American Journal of Tropical Medicine and Hygiene 23: 1110–1119, 1974

    PubMed  CAS  Google Scholar 

  • Barry VC, Buggle K, Byrne J, Conalty ML, Winder F. Absorption, distribution and retention of amino-compounds in the experimental animal. Irish Journal of Medical Science 416: 345–352, 1960

    PubMed  CAS  Google Scholar 

  • Belaube P, Devaux J, Pizzi M, Boutboul R, Privat Y. Small bowel deposition of crystals associated with the use of clofazimine in the treatment of prurigo nodularis. International Journal of Leprosy 51: 328–330, 1983

    CAS  Google Scholar 

  • Bharadwaj VP, Sritharan V, Venkatesan K, Girdhar A, Ramu G. Vitamin A levels of ichthyotic and non-ichthyotic skin and plasma of leprosy patients with and without clofazimine therapy. Indian Journal of Medical Research 75: 773–777, 1982

    PubMed  CAS  Google Scholar 

  • Browne SG, Harman DJ, Waudby A, McDougall AC. Clofazimine the treatment of lepromatous leprosy in the United Kingdom: a 12 year review of 31 cases, 1966–1978. International Journal of Leprosy 49: 167–176, 1981

    CAS  Google Scholar 

  • Browne SG, Hogerzeil LM. B663 in the treatment of leprosy: preliminary report of a pilot trial. Leprosy Review 33: 6–16, 1962

    PubMed  CAS  Google Scholar 

  • Centers for Disease Control. Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotrophic virus type III/lymphadenopathy associated virus infection. Morbidity Mortality Weekly 35: 448–452, 1986

    Google Scholar 

  • Centers for Disease Control. AIDS and HIV among health care workers. Morbidity Mortality Weekly 37: 229–234, 1988

    Google Scholar 

  • Chuaprapcislis T, Piamphongsant T. Treatment of pustular psoriasis with clofazimine. British Journal of Dermatology 99: 303–305, 1978

    Article  Google Scholar 

  • deBergeyck E, Janssens PG, de Muynck A. Radiological abnormalities of the ileum associated with the use of clofazimine in the treatment of skin ulceration due to Mycobacterium ulcerans. Leprosy Review 51: 221–228, 1980

    CAS  Google Scholar 

  • Desikan KV, Balakrishnan S. Tissue levels of clofazimine in a case of leprosy. Leprosy Reviews 47: 107–113, 1976

    CAS  Google Scholar 

  • Dill WA, Chricot L, Glazkio AJ. A new analytical procedure for B663 (clofazimine). International Journal of Leprosy 38: 355–356, 1970

    Google Scholar 

  • Duncan ME, Oakey RE. Reduced estrogen excretion due to clofazimine. International Journal of Leprosy 51: 112–113, 1983

    CAS  Google Scholar 

  • Farb H, West DP, Pedvis-Leftick A. Clofazimine in pregnancy complicated by leprosy. Obstetrics and Gynecology 59: 122–123, 1982

    PubMed  CAS  Google Scholar 

  • Feng PCC, Fenselau CC, Jacobson RR. Metabolism of clofazimine in leprosy patients. Drug Metabolism and Disposition 9: 521–524, 1981

    PubMed  CAS  Google Scholar 

  • Feng PCC, Fenselau CC, Jacobson RR. A new urinary metabolite of clofazimine in leprosy patients. Drug Metabolism and Disposition 10: 286–288, 1982

    PubMed  CAS  Google Scholar 

  • Fenselau CC, Pallante S, Parikh I. Solid phase synthesis of drug glucuronides by immobilized glucuronosyltransferase. Journal of Medicinal Chemistry 19: 679–683, 1976

    Article  PubMed  CAS  Google Scholar 

  • Grabosz JAJ, Wheate HW. Effect of clofazimine on the urinary excretion of dapsone. International Journal of Leprosy 43: 61–62, 1975

    CAS  Google Scholar 

  • Granstein RD, Sober AJ. Drug and heavy metal-induced hyper-pigmentation. Journal of the American Academy of Dermatology 5: 1–18, 1981

    Article  PubMed  CAS  Google Scholar 

  • Greene JB, Sidhu GS, Lewin S, Levine JF, Masur H, et al. Mycobacterium avium-intracellulare: a cause of disseminated life threatening infection in homosexuals and drug abusers. Annals of Internal Medicine 97: 539–546, 1982

    PubMed  CAS  Google Scholar 

  • Gidoh M, Tsutsumi S. Determination of 3 main antileprosy drugs and their metabolites in serum by HPLC. Journal of Chromatography — Biomedical Applications 223: 379–392, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hastings RC, Jacobson RR, Trautman JR. Long term clinical toxicity studies with clofazimine in leprosy. International Journal of Leprosy 44: 287–293, 1976

    CAS  Google Scholar 

  • Hawkins CC, Gold JWM, Whimbey E, Kiehn TE, Brannon P, et al. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 105: 184–188, 1986

    PubMed  CAS  Google Scholar 

  • Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs: a review. Clinical Pharmacokinetics 9: 511–544, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Mycobacterium avium-intracellulare infection. Southern Medical Journal 77: 1614, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs: a review. International Journal of Dermatology 24: 280–285, 1985a

    PubMed  CAS  Google Scholar 

  • Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clinical Pharmacokinetics 10: 532–534, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Rifampicin adverse cutaneous reactions. International Journal of Dermatology 25: 72–73, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Contact dermatitis to ethambutol. Contact Dermatitis 15: 96–97, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Contact dermatitis to the antituberculosis drugs: a review. Contact Dermatitis 15: 282–288, 1986c

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Neurological manifestations and toxicities of the antituberculosis drugs: a review. Medical Toxicology 2: 33–51, 1987a

    PubMed  CAS  Google Scholar 

  • Holdiness MR. Teratology of the antituberculosis drugs: a review. Early Human Development 15: 61–74, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Transplacental pharmacokinetics of the antituberculosis drugs. Clinical Pharmacokinetics 13: 125–129, 1987c

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. A review of iatrogenic nutritional deficiencies induced by antituberculosis drugs. Nutrition Research 7: 891–900, 1987d

    Article  CAS  Google Scholar 

  • Holdiness MR. Rifampicin drug interactions. Archives of Internal Medicine 147: 1856, 1987e

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Blood dyscrasias induced by the antituberculosis drugs: a review. Tubercle 68: 301–309, 1987f

    Article  PubMed  CAS  Google Scholar 

  • Holdiness MR. Ethionamide. In Dollery C. (Ed.) Therapeutic drugs: a clinical pharmacopoeia, Churchill Livingstone, Edinburgh, 1988a

    Google Scholar 

  • Holdiness MR. Prothionamide. In Dollery C. (Ed.) Therapeutic drugs: a clinical pharmacopoeia, Churchill Livingstone, Edinburgh, 1988b

    Google Scholar 

  • Holdiness MR. Thiacetazone. In Dollery C. (Ed.) Therapeutic drugs: a clinical pharmacopoeia, Churchill Livingstone, Edinburgh, 1988c

    Google Scholar 

  • Holdiness MR. Clofazimine in pregnancy. Early Human Development 16: in press, 1988d

  • Horsburgh CR, Mason UG, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. Medicine 64: 36–48, 1984

    Google Scholar 

  • Jacobson RR. Treatment. In Hastings (Ed.) Leprosy, pp. 193–222, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Jopling WH. Complications of treatment of clofazimine. Leprosy Review 47: 1–3, 1976

    PubMed  CAS  Google Scholar 

  • Karat ABA. Long term follow up of clofazimine in the management of reactive phases of leprosy. Leprosy Review 46s: 105–109, 1975

    Google Scholar 

  • Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampicin. Drug Metabolism Review 12: 159–218, 1981

    Article  CAS  Google Scholar 

  • Lanyi Z, Dubois JP. Determination of clofazimine in human plasma by TLC. Journal of Chromatography — Biomedical Applications 232: 219–223, 1982

    Article  PubMed  CAS  Google Scholar 

  • Levy L. Pharmacologic studies of clofazimine. American Journal of Tropical Medicine and Hygiene 23: 1097–1109, 1974

    PubMed  CAS  Google Scholar 

  • Mackey JP. Clofazimine in dermatology. International Journal of Dermatology 15: 140–141, 1976

    Article  PubMed  CAS  Google Scholar 

  • Mansfield RE. Tissue concentrations of clofazimine in man. American Journal of Tropical Medicine and Hygiene 23: 1116–1119, 1974

    PubMed  CAS  Google Scholar 

  • Masur H, Tuazon C, Gill V, Grimes G, Baird B, et al. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellular bacteremia in patients with AIDS. Journal of Infectious Diseases 155: 127–129, 1987

    Article  PubMed  CAS  Google Scholar 

  • Mehta J, Gandhi IS, Sane SB, Wamburkar MN. Effects of clofazimine and dapsone of rifampicin pharmacokinetics in multibacillary leprosy cases. Leprosy Review 57s: 67–76, 1986

    Google Scholar 

  • Moore VJ. A review of side effects experienced by patients taking clofazimine. Leprosy Review 54: 327–335, 1983

    PubMed  CAS  Google Scholar 

  • Negrel AD, Chovet M, Baquillon G, Lagadec R. Clofazimine and the eye: preliminary communication. Leprosy Review 55: 349–352, 1984

    PubMed  CAS  Google Scholar 

  • Noorden SK. The epidemiology of leprosy. In Hastings R. (Ed.) Leprosy, pp. 15–30, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Parikh I, MacGlashan DW, Fenselau CC. Immobilized glucuronsyltransferase for the synthesis of conjugates. Journal of Medicinal Chemistry 19: 296–299, 1976

    Article  CAS  Google Scholar 

  • Pavithran K. Exfoliative dermatitis after clofazimine. International Journal of Leprosy 53: 645–646, 1985

    CAS  Google Scholar 

  • Peters JH, Hamme KJ, Gordon GR. Determination of clofazimine in plasma by HPLC. Journal of Chromatography — Biomedical Applications 229: 503–508, 1982

    Article  PubMed  CAS  Google Scholar 

  • Pfaltzgraff RE. The control of neuritis in leprosy with clofazimine. International Journal of Leprosy 40: 392–398, 1972

    CAS  Google Scholar 

  • Revill WDL, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2: 873–877, 1973

    Article  PubMed  CAS  Google Scholar 

  • Rosmusen I. Pyoderma gangrenosum treatment with clofazimine. Clinical evaluation of 7 cases. Acta Dermato-Venereologica 63: 552–553, 1983

    Google Scholar 

  • Sansarricq H. Leprosy in the world today. Leprosy Review 54s: 7–16, 1983

    Google Scholar 

  • Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. Pharmacokinetics of clofazimine in healthy human volunteers. International Journal of Leprosy 55: 9–15, 1987

    CAS  Google Scholar 

  • Venencie PY, Cortez A, Orieux G, Jost JL, Chomette G, et al. Clofazimine enteropathy. Journal of the American Academy of Dermatology 15: 290–291, 1986

    Article  PubMed  CAS  Google Scholar 

  • Venkatesan K, Bharadwaj VP, Ramu G, Desikan KV. Study on drug interactions. Leprosy in India 52: 229–236, 1980

    PubMed  CAS  Google Scholar 

  • Venkatesan K, Mathur A, Girdhan BK, Bharadwaj VP. The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Journal of Antimicrobial Chemotherapy 18: 715–718, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vischer WA. The experimental properties of G30,320 (B633). Leprosy Review 40: 107–111, 1969

    PubMed  CAS  Google Scholar 

  • Wallace JM, Hannah JB. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Chest 93: 926–932, 1988

    Article  PubMed  CAS  Google Scholar 

  • Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review of the microbiological and clinical aspects. Review of Infectious Diseases 9: 275–294, 1987

    Article  CAS  Google Scholar 

  • Working Party on B663: Symposium on B663 (Lamprene, Geigy) in the treatment of leprosy and leprosy reactions. International Journal of Leprosy 36: 560–561, 1968

    Google Scholar 

  • World Health Organization. Expert committee on leprosy 1977 fifth report. World Health Organization Technical Report Series Number 607, 1977

  • World Health Organization. Chemotherapy of leprosy for control programs. Report of a WHO study group. World Health Organization Technical Series Number 675, 1982

    Google Scholar 

  • Yajko DM, Nassos PS, Hadley WK. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrobial Agents and Chemotherapy 31: 117–120, 1987

    Article  PubMed  CAS  Google Scholar 

  • Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Leprosy Reviews 50: 135–144, 1979

    CAS  Google Scholar 

  • Young LS. Mycobacterium avium complex infection. Journal of Infectious Diseases 157: 863–867, 1988

    Article  PubMed  CAS  Google Scholar 

  • Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clinical Pharmacokinetics 11: 299–315, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lakeside Hospital, Suite 207 - Medical Office Building, 4720 I-10 Service Road, Metairie (New Orleans), Louisiana, 70001, USA

    Mack R. Holdiness

Authors
  1. Mack R. Holdiness
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holdiness, M.R. Clinical Pharmacokinetics of Clofazimine. Clin-Pharmacokinet 16, 74–85 (1989). https://doi.org/10.2165/00003088-198916020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198916020-00002

Keywords

Search

Navigation